Posted by Michael Wonder on 16 Jun 2018
Adding pertuzumab to existing treatments after surgery for early breast cancer not cost effective, says NICE in draft guidance
15 June 2018 - Women with a type of early breast cancer may not benefit from continuing or starting a drug after having surgery, NICE says in draft guidance.
Continuing or starting with pertuzumab alongside trastuzumab and chemotherapy after surgery for women with HER2 positive cancer may not extend their life and is not cost effective, the draft guidance says.
NICE already recommends pertuzumab (also called Perjeta and made by Roche), given with trastuzumab and chemotherapy, for treating early HER2-positive breast cancer before surgery. NICE also recommends it for treating HER2-positive breast cancer that has either recurred in the breast following initial treatment or has spread from the breast to elsewhere in the body.
